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Loss to follow-up (LTFU) is a serious issue in the field of tuberculosis (TB) since 
it can lead to TB outbreaks and drug resistance. The proportion of LTFU patients 
differs among different countries, regions, year, and institutions. In some countries, 
the number of patients that were LTFU nearly reaches half of the total patients. 
Underlying factors such as age, gender, education, residence, financial factors, 
migration, and social stigma are discussed in this chapter. These factors should 
always be taken into consideration whenever a treatment program is designed. 
Suggestions have been made regarding some interventions that could potentially 
solve the problem of LTFU. With these points in mind, an ambitious approach 
should be taken to reduce the number of LTFU patients up to zero.
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1. Introduction
Tuberculosis (TB) is a disease, which requires more than just biomedical treat-
ment. WHO-recommended standard TB treatment requires a minimum duration of 
6 months. The patients have to regularly take treatment without interruption to get 
a cure. However, discontinuation of treatment because of loss to follow-up (LTFU) 
is a significant problem, especially among patients suffering from multidrug-resis-
tant tuberculosis (MDR-TB), requiring urgent attention. The proportions of LTFU 
and its associated factors differ among various countries. A clear understanding of 
these underlying causes is essential for the success and effectiveness of the National 
Tuberculosis Program (NTP) of every nation. Hence, appropriate measures target-
ing LTFU are needed to achieve the goals of the NTP.
2. Definition
In 2012, a large group of researchers from Africa, Asia, America, Europe, and the 
Pacific suggested that the term ‘defaulter’ is inappropriate for the patient [1]. Instead, 
they recommended using the term ‘person lost to follow-up’ to become more patient-
centered. In 2013, the WHO decided to use the term ‘loss to follow-up’ instead of 
‘defaulter’ for reporting treatment outcomes because the former is less judgmental 
[2]. They defined LTFU as “A TB patient who did not start treatment or whose treat-
ment was interrupted for 2 consecutive months or more.” Since then, several papers 
have started reporting according to this new term and definition [3–10].
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3. The problem of LTFU
The patients who were LTFU have not completed the treatment regime. This 
can cause serious public health problems because these patients are at higher risk 
of drug resistance [11]. They continue to spread the potentially resistant bacilli to 
the public, infecting the public. This has been proved in a Bayesian mapping where 
LTFU has served as an important indicator for the distribution of TB patients [12]. 
Therefore, LTFU should be one of our primary concerns in the battle against TB.
Even just a single case of LTFU could cause an outbreak of TB, as observed in 
countries with low incidence such as Norway [13, 14], USA [15], and Austria [16]. 
In such outbreaks, the index cases are mostly immigrants, spreading the infection to 
their families, friends, and other social networks. To further visualize this problem, 
we need to look into the proportion of LTFU among different countries in the 
world.
4. Proportion of LTFU
The proportion of LTFU varies considerably among different countries, different 
types of TB, and different patient populations. It has been studied extensively and 
was found to be ranging from 2.5 to 44.9% [17–23]. A very high proportion (44.9%) 
of the patients were LTFU in rural northern Mozambique revealing that LTFU is 
a very serious problem [19]. In addition, systematic reviews and meta-analyses 
have estimated the mean proportion of multidrug-resistant TB patients who were 
LTFU. A 2009 systematic review of MDR-TB patients has found that this proportion 
is 12% [24]. Another 2009 systematic review also found a similar proportion of 13% 
[25]. However, a 2012 individual patient data meta-analysis found a higher propor-
tion of 23% [26]. A rough literature review has revealed that the proportion of MDR 
TB patients who were LTFU ranges from 2.2 to 47% [27–43]. The figures vary vastly 
among different years, countries, and institutions, suggesting that the underlying 
factors responsible for these variations should be studied carefully.
However, few studies have reported on the proportion of LTFU among patients 
with extra-pulmonary TB. According to a French study, this proportion was 25% 
among lymph node TB patients [44]. Another study from Gabon reported that the 
proportion among cervical lymph node TB patients was 24.3% [45]. In India, among 
the miliary tuberculosis patients presenting with neurological manifestations, the 
proportion was 10% [46]. However, in Saudi Arabia, the proportion among CNS 
tuberculoma patients was reported to be 25.8% [47].
Another area of interest is latent TB since developed countries such as the USA 
and the UK are giving much attention to latent TB and its LTFU rate. Studies from 
the USA reported proportions ranging from 12 to 35.6% [48, 49]. In the UK, this 
proportion is 22.8% [50], and in Switzerland, 11% [51].
Attention should also be paid toward LTFU among certain special populations. 
The proportion of LTFU among childhood TB patients ranges from 4 to 37% 
[52–57]. Among the children with drug-resistant TB, it ranges from 5 to 19.09% 
[58–60]. These figures are much similar to those of the adult population. On the 
other hand, researchers from Côte d’Ivoire found out that the proportion of LTFU 
was rising among the elderly TB patients [61]. This is an area that researchers 
should explore more in the future.
We should not forget about our fellow healthcare workers since LTFU could lead 
to serious problems in the healthcare service setting. They are expected to have low 
rates of LTFU because of the medical knowledge they possess. Fortunately, a study 
from Morocco confirmed that the proportion of LTFU among healthcare workers 
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in the public sector was only 0.8% [62]. However, many studies need to be done to 
explore this area of study.
Other populations of interest are prisoners and migrants. Northern Ethiopian 
prisons reported a low LTFU proportion of only 2.5% [63], which is an excellent 
result. In contrast, among the Ugandan prison inmates, 43% were LTFU and the 
odds are greater among the transferred prisoners [64]. On the other hand, research-
ers from the USA found out that 25.8% of the cases in a public health intervention 
were LTFU, and they were mainly undocumented migrants [65]. In such countries, 
as discussed above, even a single case of LTFU can cause an outbreak of TB. The 
same problem is arising in Australia where all of the detained illegal foreign fisher-
men were LTFU [66]. They concluded that
“Treatment completion in illegal foreign fishermen may be as low as zero; 
deporting fishermen before curative treatment is completed undermines TB control 
efforts and may lead to an emergence of drug resistance and an increased burden of 
active TB disease in our region.”
This is an area of concern that needs urgent measures. On the other hand, 
the International Organization of Migration is achieving great results among 
Vietnamese immigrants [67]. Only 7% of the MDR-TB patients from these migrants 
were LTFU. It is likely that such ‘international intergovernmental’ effort is necessary 
to tackle the problem of LTFU among the migrants since individual governments 
are facing difficulties handling this problem.
5. Factors associated with LTFU
5.1 Individual factors
Individual factors play a role in the process of being LTFU from treatment. 
Sometimes, the results may contradict between different studies, probably due to 
the cultural, social, and other variations of the study settings.
Among the various sociodemographic characteristics, age is a recognized factor 
associated with LTFU. Studies from India, Brazil, and China revealed that elderly 
patients have higher LTFU [4, 68–70], whereas studies from Norway, Botswana, and 
South Africa suggested that adolescents have significant risk [8, 30, 71]. One study 
from the UK even suggested a wider range of age of 15–44 years as a high-risk group 
for LTFU [11]. Regarding gender, studies uniformly suggest that higher LTFU was 
found in males, as seen in Kenya, Ethiopia, Georgia, and Uzbekistan [7, 18, 41, 72].
Residence plays a role in the mechanism of LTFU. In Pakistan, the rural resi-
dence is associated with LTFU [73], whereas in Uzbekistan, the urban residence is 
associated with LTFU [18]. This may be caused by access to the treatment center 
since being far from the treatment center is also associated with LTFU [74]. 
Transportation should be improved to increase accessibility toward the treat-
ment center. Alternatively, they could be built in the hard-to-reach areas. Both 
approaches include challenges, and ultimately, these challenges may be what cause 
LTFU. Further discussion regarding different providers will be given in the next 
section.
Education plays a role in the development of LTFU. Brazilian researchers have 
found out that less than 8 years of schooling increases the risk of LTFU [4]. In addi-
tion, scarce TB knowledge is a risk factor for LTFU [75], and better TB knowledge 
a protective factor [5]. Therefore, health education and proper counseling should 
always be at the heart of every anti-TB treatment program.
Financial factors should also be considered while giving treatment, and pro-
grams without such considerations will likely to result in high LTFU. A study from 
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Uzbekistan found that joblessness contributes toward LTFU [18]. This is confirmed 
by a study from China which found that pre-school children, unemployed labor-
ers, and retirees have a higher rate of LTFU [76]. Patients with low income have 
financial constraints to complete treatment leading to LTFU as seen in India [77], a 
lower middle-income country. A similar phenomenon has been observed in South 
Korea, a high-income country [78]. Even in the USA, it was found that homeless-
ness is associated with LTFU [79, 80], which might be due to low income. Therefore, 
regardless of the country, patients with low income still have barriers against treat-
ment completion.
LTFU is also associated with alcohol abuse, tobacco use, smoking, and illicit 
drug use. Association between alcoholism and LTFU was observed in India [77], 
Philippines [5], and Congo [74], tobacco use in Georgia [41], smoking in Brazil 
[75], and illicit drug use in Norway [30], Georgia [41], and the UK [81]. Therefore, 
before initiating treatment, personal history should be carefully taken to find out 
these risk factors, and special attention should be given to such patients.
There are also certain disease-specific factors that are associated with 
LTFU. Those who were previously LTFU tend to be LTFU again. This was 
confirmed by studies conducted in Brazil [4], Kenya [7], Uzbekistan [18], 
and Korea [78]. Caution should be taken while planning treatment for such 
patients. Studies from Nigeria and Ethiopia both point out that smear-negative 
TB patients were more likely to be LTFU [72, 82]. However, the opposite was 
observed in the UK where smear-positive pulmonary TB patients were more 
likely to be LTFU [11]. Researchers also found that patients with extrapulmonary 
TB were more likely to be LTFU [71, 83]. Co-morbid diseases such as diabetes 
mellitus and human immunodeficiency virus (HIV) infection also cause hin-
drance against TB treatment conditions [7, 71, 84].
5.2 Treatment support services
The treatment providers should give support to the patients since a perceived 
lack of provider support is a barrier to regular follow-up [77], and receiving any 
type of assistance and support from the providers can protect against LTFU [5]. 
They need to build up trust [5] from the patients. An intervention program target-
ing these factors will be described later in the chapter. Lastly, the timing of the 
treatment services should be flexible according to the needs of the patients [77], but 
this may not be an easy task to implement.
5.3 Diagnosis and treatment
The timing of the treatment is important since those who initiate the treatment 
late (beyond and within 30 days of onset) are more likely to be LTFU [85]. Those 
who initiate it late may not have enough motivation, will, or knowledge to continue 
taking treatment until they are cured. Moreover, the timing of treatment interrup-
tion is found to be the most important during the intensive phase [7]. This stage 
should be particularly targeted while conducting interventions against LTFU.
Different providers have different abilities to retain the patients. In Korea, 
patients treated by a non-pulmonologist were found to be more likely to default 
from TB treatment [78]. In Myanmar, patients treated by private practitioners 
were more likely to be LTFU [86]. An interesting situation was observed in 
Nigeria where patients treated at private, not-for-profit (PNFP) DOT facili-
ties were more likely to be LTFU [87]. The researchers concluded that “Patients 
managed at PFP [private, for-profit] DOT facilities were probably richer, had 
better education, nutrition, and knowledge of TB than patients managed at PNFP 
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DOT facilities…” Indeed, the factors causing LTFU are not simple, and they are 
correlated with each other. Therefore, intervention should be addressed not only 
on a single problem but also targeted toward the patient as a whole. Furthermore, 
the provider should also be consistent throughout the different stages of treat-
ment since different providers in the intensive phase and continuation phase are 
associated with LTFU [88].
5.4 Drug side effects
Studies from the USA and India have found that drug side effects are associated 
with LTFU [49, 77]. The researchers from the Philippines take one step further 
regarding this concept, stating ‘patients’ self-rating of the severity’ as an associ-
ated factor [5]. Indeed, some side effects, such as hepatitis, of the anti-tuberculosis 
drugs are already severe. However, some side effects, such as vomiting, might need 
self-rating since different patients may perceive differently. It would be interesting 
to research which kind of patient rates which side effect as severe.
5.5 Social factors
Factors such as migration and social stigma also contribute toward LTFU. LTFU 
is common among the migrant population particularly in developed countries 
where there is an inward movement of people from the developing countries. 
Studies from the UK had repeatedly revealed this association [11, 50, 86, 89]. 
Researchers from the USA also found that birth outside the USA or Canada is associ-
ated with LTFU [80]. Higher LTFU among migrants has also been observed in Asian 
countries such as South Korea and China [70, 76, 90].
In countries where TB is a social stigma, treatment is very difficult and sensitive [77]. 
The patients may not want the health workers to give counseling. They do want to take 
treatment since the news of having TB may spread to the community, causing discrimi-
nation. In such places, secret treatment sessions should be initiated to control LTFU 
rates. In contrast, in Korea, the absence of TB stigma is associated with LTFU [78]. The 
authors wrote “TB stigma might motivate patients to receive TB treatment, thus increas-
ing adherence to TB treatment.” Therefore, before starting the TB treatment program, 
it is important to make community observations first to find out whether TB sigma can 
cause or prevent LTFU.
In theory, interpersonal factors such as family dynamics, household role, peer 
influence, and partner and family relationships were thought to influence LTFU [5]. 
However, to our knowledge, none of the studies to date supports the association of 




Living in an institution 2
Previous anti-TB treatment 2
Poor patient understanding 2
Intravenous drug use (IDU) 4
Unknown IDU status 1
Table 1. 
A predictive scoring instrument for tuberculosis lost to follow-up outcome [86].
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5.6 Scoring instrument
Based on the factors associated with LTFU, Rodrigo et al. have developed a scoring 
instrument to predict the probability of LTFU (Table 1) [91]. According to their origi-
nal paper, “Scores of 0, 1, 2, 3, 4 and 5 points were associated with a lost to follow-up 
probability of 2.2% 5.4% 9.9%, 16.4%, 15%, and 28%, respectively.” Incorporating 
the instrument in the process of history taking could help the healthcare providers in 
identifying patients who have the potential to be LTFU. Further interventions should be 
carried out to prevent these patients from becoming LTFU. Similar scoring systems could 
be developed in different regions, since there are always country-specific variations.
6. Interventions
6.1 Directly observed treatment (DOT)
Indeed, DOT is a part of the WHO-recommended ‘Directly Observed 
Treatment Short Course’ (DOTS) strategy. Although it cannot be denied that this 
strategy has saved the lives of millions of TB patients, the strategy itself is not flaw-
less. Several authors have questioned the effectiveness of DOT as summarized in a 
review article by Otu [92]. The 2015 Cochrane systematic review and meta-analysis 
on DOT compared it with self-administered treatment, and the authors concluded 
that “TB cure and treatment completion were low with self-administered therapy 
in these trials, and direct observation did not substantially improve this” [93]. 
They called for complementary and alternative strategies in addition to DOT. Since 
DOT is a well-known and well-documented intervention in the field of TB, we felt 
that it need not be described in further detail in this chapter. Some interventions 
that have the potential to correct the weaknesses of DOT will be discussed below.
6.2 mHealth
Recently, mHealth has emerged as a popular choice for health programs around 
the world. The Global Observatory for eHealth (GOe) has defined mHealth as 
“medical and public health practice supported by mobile devices, such as mobile 
phones, patient monitoring devices, personal digital assistants (PDAs), and other 
wireless devices” [94]. Among these mHealth initiatives, appointment remind-
ers and treatment compliance initiatives are of interest in reducing the rate of 
LTFU. However, there are limited interventional studies evaluating the effectiveness 
of these interventions in reducing the risk of LTFU.
In 2017, Hermans et al. have evaluated a text message service in the Infectious 
Diseases Institute (IDI) in Kampala, Uganda [95]. In this quasi-experimental study, 
appointment reminders were sent the day before the appointment, and adherence 
reminders were sent on days 2, 7, and 11 after the appointment. A total of 96% of the 
participants rated the messages as being helpful, and qualitative results also confirm 
these findings. However, data analysis has revealed that there was no statistically sig-
nificant difference in the risk of LTFU between the intervention and control group. 
The lack of statistical significance may be due to the small sample size. Therefore, 
further studies with larger sample sizes are needed to further evaluate the program.
6.3 eCompliance
eCompliance is a biometric-based program, developed by Operation ASHA 
(OpASHA) [96], an Indian not-for-profit organization founded in 2006. The 
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system is similar to mHealth in using text message alerts to inform the missed dose. 
However, the unique fingerprint verification system for the patient and the health 
worker takes mHealth to the next level. The OpASHA website explains the working 
mechanism of eCompliance as follows.
“During each patient visit, the patient and healthcare worker simultaneously scan 
their finger in the system, the medication is dispensed, and the treatment is recorded 
in the system’s database. If a patient misses a dose, an SMS message alert is sent 
to the patient, healthcare worker and supervisor. The healthcare worker is then 
responsible to meet the patient within 24–48 hours to administer and record the 
treatment.”
This system can be used to reduce the risk of LTFU since the data from OpASHA 
stated that the LTFU rate is less than 4% using their system [96].
This claim by OpASHA has been put to test in Uganda by Snidal et al. in 2012 
[97]. Community health workers (CHWs) were selected and trained to use the 
system. The intervention was conducted at the Millennium Villages Project (MVP) 
cluster in Ruhiira, Uganda. The patients were followed-up by CHWs until the end 
of the treatment period. The proportion of LTFU is surprisingly 0% in the interven-
tion group, which is a significant reduction compared to the control group, yielding 
an excellent result. However, since this study suffers from a limited sample size, a 
large-scale interventional study is still necessary to confirm the results. Local adap-
tation to the software is available from OpASHA, and they should be incorporated 
into local national tuberculosis programs to lower the proportions of LTFU.
6.4 Community-based programs
An innovative community-based intervention to improve TB treatment out-
comes was conducted in Sidama zone, Ethiopia [98, 99]. The core health workers 
mainly responsible for delivering the intervention to the grass-root level were called 
the health extension workers (HEWs). The HEWs were trained and salaried female 
health workers from the respective intervention regions. Active case finding and 
sputum smear preparation were conducted by the HEWs. The supervisors process 
the smears and initiate anti-TB treatment. Again, HEWs provide treatment support 
which includes provision and monitoring of treatment. Evaluation of the program 
over 4.5 years revealed that the proportion of patients lost to follow-up decreased 
significantly up to 3% [99]. The authors concluded that
“We have thus demonstrated that bringing simple services that detect disease and 
provide treatment support close to where patients live is critical to increase access 
to TB diagnosis and treatment adherence and minimise the number of patients 
LTFU.”
Therefore, such community-based programs should be implemented in modi-
fied forms in different countries around the world to reduce the proportion of 
LTFU. Another important thing to note is that both this program and eCompliance 
mentioned above employed ‘task shifting’ toward basic health workers (CHWs and 
HEWs) to support TB treatment at the grass-root level, not the experts.
6.5 Social support programs
In 2013, a novel social support program was developed in India by forming 
groups called “treatment support group (TSG)” [100].
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“A TSG is a non-statutory body of socially responsible citizens and volunteers to provide 
social support to each needy TB patient safeguarding his dignity and confidentiality by 
ensuring access to information, free and quality services and social welfare programs, 
empowering the patient for making decision to complete the treatment successfully.”
A TSG supports the various needs of the patient so that they can complete 
the anti-TB treatment without any worries. The package includes transportation 
service, treatment counseling, emotional and spiritual support, and providing 
accommodation for homeless TB patients. After the program was implemented, the 
rate of LTFU fell until it strikes zero in the latest cohorts. It is because it tackles the 
social dimension associated with LTFU. This is one program that the interviewed 
patients from Ethiopia, who were LTFU, had hoped for [101].
6.6 Legislation
In some countries, under certain circumstances, law enforcement is controversially 
used to solve the problem of LTFU. Usually, the patients who were LTFU were isolated 
in hospitals, but in some countries, they were isolated in prisons. Usually, this method 
was used against patients who were homeless and had a history of alcohol abuse [102]. 
When all the other methods fail, the medical officer, with the power given by the 
health laws, has to conduct a short-term incarceration of the patients who were LTFU.
Detention of patients includes ethical and human right problems. The con-
troversy surrounding this issue has been discussed in detail in a review article 
by Mburu et al. [103]. They discussed that the primary reason for detention is 
to protect public health, according to the Siracusa Principles adopted by the UN 
Economic and Social Council. However, they argued that this conflicts with the 
international human right laws and the 1979 Alma-Ata Declaration.
“…incarceration and detention approaches curtail the rights to health, informed consent, 
privacy, freedom from non-consensual treatment, freedom from inhumane and degrad-
ing treatment, and freedom of movement of people lost to follow-up. Detention could 
also worsen social inequalities and lead to a paradoxical increase in TB incidence.”
In the light of this information, the interventions which tackle the risk factors 
associated with LTFU are far superior to detention, which provides just a temporary 
solution to the problem, not a permanent one.
Another form of federal public health intervention is used in the USA to solve 
the problem of LTFU among the migrants [65]. These tools called the Do Not Board 
(DNB) and Border Lookout (BL) list are managed by the Department of Homeland 
Security (DHS) according to requests from the Centers for Disease Control and 
Prevention (CDC) Travel Restriction and Intervention expert workgroup. They are 
designed to detect land border travelers who were LTFU from TB treatment. State 
health departments and local health jurisdictions supply the list of patients and 
were reviewed under the following criteria:
“(1) infectiousness or potential infectiousness with a communicable disease that 
would pose a public health threat if the individual travelled internationally;
(2) the person is unaware of his/her diagnosis, fails to adhere to public health 
recommendations, including treatment, or public health authorities are unable to 
locate the person; and
(3) the person poses a risk to travel internationally or on a commercial flight” [65].
9© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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Analysis revealed that most of the patients from this list were successfully 
treated but most of the migrants remain LTFU, suggesting that some improvement 
to the program is still needed to handle this problem.
7. Conclusion
LTFU from treatment is a serious problem that cannot be ignored. Throughout 
this chapter, the consequences of LTFU, the magnitude of this problem in differ-
ent countries, and the underlying factors have been discussed. Various researchers 
have designed potentially powerful interventions to tackle LTFU. But, we still need 
further evidence and actions to be able to successfully lower the number of patients 
that are LTFU. With these points in mind, it is suggested that an ambitious approach 
should be taken to reduce the number of LTFU patients up to 0%.
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